Expression of a recombinant monoclonal antibody from a bicistronic mRNA

Hybridoma

Volumn 16, Issue 5, 1997, Pages 421-426

  Kolb, Andreas F ^a,b   Siddell, Stuart G ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b HANNAH RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MESSENGER RNA; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; GENE EXPRESSION; IMMUNOGLOBULIN VARIABLE REGION; MOLECULAR CLONING; MOUSE; MURINE HEPATITIS CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS;

EID: 0030695272     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1997.16.421     Document Type: Article

References (21)

1. Siddell SG: The Coronaviridae: An introduction. In: The Coronaviridae, SG Siddell (Ed.). Plenum Press, New York, 1995;1-10.
2. Wege H, Siddell SG, and ter Meulen V: The biology and pathogenesis of coronaviruses. Curr Top Microbiol Immunol 1982;99:165-200.
3. Dales S, and Anderson R: Pathogenesis and diseases of the central nervous system caused by murine coronaviruses. In: The Coronaviridae, SG Siddell (Ed.). Plenum Press, New York, London, 1995;257-292.
4. Even C, Rowland RR, and Plagemann PG: Mouse hepatitis virus infection of mice causes long-term depletion of lactate dehydro-genase-elevating virus-permissive macrophages and T lymphocyte alterations. Virus Res 1995;355-364.
5. Wege H, Dörries R, and Wege H: Hybridoma antibodies to the murine coronavirus JHM: Characterization of epitopes on the peplomer protein E2. J Gen Virol 1984;65:1913-1941.
6. Gallagher TM, Parker SE, and Buchmeier MJ: Neutralisation-resistant variants of a neurotropic coronavirus are generated by deletions within the amino-terminal half of the spike glycoprotein. J Virol 1990;64:731-741.
7. Routledge E, Stauber R, Pfleiderer M, and Siddell SG: Analysis of murine coronavirus surface glycoprotein functions by using monoclonal antibodies. J Virol 1991;65:254-262.
8. Enjuanes L, and van der Zeijst BAM: Molecular basis of transmissible gastroenteritis virus epidemiology. In: The coronaviridae, SG Siddell (Ed.). Plenum Press, New York, 1995;337-376.
9. Sandhu JS: Protein engineering of antibodies. Crit Rev Biot 1992;12:437-462.
10. Wawrzynczak EJ: Rational design of immunotoxins: Current progress and future prospects. Anticancer Drug Des 1992;7:427-441.
11. Adair JR: Engineering antibodies for therapy. Immunol Rev 1992;130:5-40.
12. Orlandi R, Güssow DH, Jones PT, and Winter G: Cloning immunoglobulin domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 1989;86:3833-3837.
13. Walls MA, Hsiao K, and Harris LJ: Vectors for the expression of PCR-amplified immunoglobulin variable domains with human constant regions. Nucl Acids Res 1993;21:2921-2929.
14. Köhler G: Immunoglobulin chain loss in hybridoma lines. Proc Natl Acad Sci USA 1980;77:2197-2199.
15. Ghattas IR, Sanes JR, and Majors JE: The encephalomyocarditis virus internal ribosomal entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol 1991;11:5848-5859.
16. Kumanishi T: Brain tumors induced with Rous sarcoma virus, Schmidt-Ruppin strain. I. Induction of brain tumors in adult mice with Rous chicken sarcoma cells. Jap J Exp Med 1967;37:461-474.
17. Kolb AF, and Siddell SG: Genomic targeting with an MBP-Cre fusion protein. Gene 1996;183:53-60.
18. Kolb AF, Maile J, Heister A, and Siddell SG: Characterization of functional domains in the human coronavirus HCV 229E receptor. J Gen Virol 1996;77:2515-2521.
19. Clark AJ, Cowper A, Wallace R, Wright G, and Simons JP: Rescuing transgene expression by co-integration. Biotechnology 1992;10:1450-1454.
20. Günzburg WH, Salmons B, Schlaeffli A, Moritz-Legrand S, Jones W, Sarkar NH, and Ullrich R: Expression of the oncogenes mil and ras abolishes the in vivo differentiation of mammary epithelial cells. Carcinogenesis 1988;9:1849-1856.
21. Bebbington CR, Renner G, Thomson S, King D, Abrams D, and Yarranton GT: High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology 1992;10:169-175.